赛尼哌在肝脏移植中的应用

 目的探讨肝移植中1剂赛尼哌方案的可行性.方法回顾性研究该中心2002年9月～2004年3月间的148例实施过肝脏移植手术患者的用药方案,统计1剂组和2剂组的排斥反应、院内感染发生率,分析两组之间的差异.结果总排斥反应发生率为6.08%,2剂组发生率为5.56%,1剂组为6.15%.总感染发生率为8.78%,2剂组发生率为11.11%,1剂组为8.46%.两组间排斥反应发生率差异无统计学意义(P＞0.05);两组间院内感染发生率差异无统计学意义(P＞0.05).结论1剂赛尼哌方案在国人免疫抑制方案中能提供安全的免疫诱导,与2剂方案无显著性差异.

Use of single-dose daclizumab in liver transplantation

Objective To evaluate the efficacy of single-dose daclizumab in liver transplantation.Methods A retrospective study was carried out on 148 patients who received Liver transplantation from September 2002 to March 2004.The incidence rates of rejection and nosocomial infection in single-dose and two-dose daclizumab groups were analysed statistically using software SPSS11.5.Results The total incidence rates of rejection and nosocomial infection were 6.08% and 8.78%,respectively;the incidence rate of rejection in two-dose group was lower than that in single-dose group, whereas the nosocomial infection rate was on the contrary.But there was no significant difference between the two groups either in the rejection rate or in the nosocomial infection rate (P>0.05).Conclusions Single-dose daclizumab after liver transplantation is a safe immunosuppressive regimen in Chinese;there is no significant difference between single-dose and two-dose daclizumab.